September 7, 2017
Biocartis product revenues grew 195% in first half 2017
Commenting on the H1 2017 results, Hilde Windels, interim Chief Executive Officer Biocartis (until 31 August 2017), said that the…
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
September 7, 2017
FDA puts on hold three Opdivo-based combination studies in multiple myeloma
The U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on three Opdivo-based combination clinical studies in…
September 7, 2017
Vertex takes Ironwood Pharmaceuticals’ CFO Tom Graney
Vertex Pharmaceuticals Incorporated on Wednesday announced the appointment of Tom Graney as the Senior Vice President and Chief Financial Officer (CFO).
September 5, 2017
AZ welcomes new members to the Board
AstraZeneca ob Tuesday announced the appointment of Sheri McCoy and Deborah DiSanzo as Non-Executive Directors of the company. McCoy will also become a member of the Audit Committee.
September 5, 2017
TiGenix gets more space at its expanded production facility in Madrid
TiGenix NV has obtained a license for the commercial production of expanded adipose-derived stem cells (eASCs) at its expanded manufacturing facility in Madrid.
September 5, 2017
Multiple sclerosis 10-17 patients look to Novartis’s fingolimod study
Novartis on Tuesday announced positive results from the Phase III PARADIGMS study, investigating the safety and efficacy of oral once-daily…
September 5, 2017
Biocartis gets FDA clearance for Idylla Respiratory
Biocartis Group got clearance for the Idylla Respiratory (IFV-RSV) Panel from the US Food and Drug Administration (FDA). Idylla Respiratory…
September 4, 2017
Novartis CEO Jimenez to retire after eight years
Joseph Jimenez, Chief Executive Officer (CEO) of Novartis, step down as CEO in 2018, after eight years in position. To…
September 1, 2017
Global Vaccines Market to reach US$ 60 Billion by the year 2022. Pediatric vaccines market is having a dominant market share compared…
August 31, 2017
Amgen’s research: when a patient relapses, KYPROLIS should replace Velcade
Amgen posted positive results from a post-hoc analysis requested by the U.S. Food and Drug Administration (FDA) of the Phase 3 head-to-head ENDEAVOR trial, which followed patients for at least three years after enrollment.